Xitra Therapeutics GmbH

Xitra Therapeutics GmbH is a biotechnology company dedicated to the discovery and development of innovative small molecules targeting the Mas and MrgD receptors within the Alternative Renin-Angiotensin System. These molecules mimic the naturally occurring peptide angiotensin-(1-7) but offer enhanced drug properties, including increased potency and oral bioavailability. As a subsidiary of Constant Therapeutics, Xitra Therapeutics leverages cutting-edge research to develop therapies aimed at treating common and rare diseases. Our mission is to advance scientific knowledge and translate it into effective treatments that improve patient outcomes.